CoChat

Comparative study between the effect of the peroxisome proliferator activated receptor-α ligands fenofibrate and n-3 polyunsaturated fatty acids on activation of 5′-AMP-activated protein kinase-α1 in high-fat fed rats

Open access
Motawi, Tarek M Kamal, Hashem, Reem M, Rashed, Laila A, El-Razek, Sabry M Abd · 2009 · Journal of Pharmacy and Pharmacology
Cited by 30

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Objectives: Obesity is a risk factor for type 2 diabetes mellitus. It results from an energy imbalance in which energy intake exceeds energy expenditure. The cellular fuel gauge 5′-AMP-activated protein kinase (AMPK) is a heterotrimeric protein consisting of one catalytic subunit (α) and two non-catalytic subunits (β and γ), and approximately equal levels of α1 and α2 complexes are present in the liver. AMPK regulates metabolic pathways in response to metabolic stress and in particular ATP depletion to switch on energy-producing catabolic pathways such as β-oxidation of fatty acids and switch off energy-depleting processes such as synthesis of fatty acid and cholesterol. A high-fat diet alters AMPK-α1 gene expression in the liver and skeletal muscle of rats and results in body weight gain and hyperglycaemia. The aim of this study was to investigate and compare the potential effects of peroxisome proliferator-activated receptor (PPAR)-α agonists fenofibrate and n-3 polyunsaturated fatty acids (PUFAs) in modulation of AMPK-α1 activity in liver and skeletal muscle of high-fat diet fed rats. Methods: Reverse transcription–polymerase chain reaction was used for determination of AMPK-α1 in liver and soleus muscle and both PPAR-α and CPT-1 in hepatic tissues. Serum, total cholesterol, triacylglycerol, fatty acid and fasting blood glucose were determined colorimetrically. Key findings: Both PPAR-α agonists, fenofibrate and n-3 PUFA, increased the mRNA expression of AMPK-α1 activity in liver and skeletal muscle of obese diabetic rats. Fenofibrate was superior in its activation of hepatic mRNA expression of AMPK-α 1 to exert more lipolytic effect and body weight reduction, as estimated through the decrease of triacylglycerol output and serum levels of fatty acid on the one hand and the increase in CPT-1 mRNA expression, the key enzyme in β-oxidation of fatty acid, on the other hand. n-3 PUFA activated AMPK-α1 mRNA expression in skeletal muscle much more than fenofibrate to reveal more hypoglycaemic effect. Conclusions: The PPAR-α agonists fenofibrate and n-3 PUFA could efficiently activate AMPK-α1 mRNA expression in liver and skeletal muscle to exert body weight reduction and hypoglycaemic effect, respectively.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1211/jpp.61.10.0010

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 36

  1. Friedman, 2000, Obesity in the new millennium, Nature, 404, 632, 10.1038/35007504 · DOI · Paper page
  2. Kopelman, 2000, Obesity as a medical problem, Nature, 404, 635, 10.1038/35007508 · DOI · Paper page
  3. Hellström, 2004, Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects, Br J Nutr, 92, S47, 10.1079/BJN20041142 · DOI · Paper page
  4. Carling, 2007, The role of the AMP-activated protein kinase in the regulation of energy homeostasis, Novartis Found Symp, 286, 72, 10.1002/9780470985571.ch7 · DOI
  5. Stapleton, 1997, AMP-activated protein kinase isoenzyme family: subunit structure and chromosomal location, FEBS Lett, 409, 452, 10.1016/S0014-5793(97)00569-3 · DOI · Paper page
  6. Woods, 2000, Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase, Mol Cell Biol, 20, 6704, 10.1128/MCB.20.18.6704-6711.2000 · DOI · Paper page
  7. Lev, 1995, Protein tyrosine kinase PYK2 involved in Ca2+- induced regulation of ion channel and MAP kinase functions, Nature (London), 376, 737, 10.1038/376737a0 · DOI · Paper page
  8. Barnes, 2002, Isoform-specific regulation of 5′ AMP-activated protein kinase in skeletal muscle from obese Zucker (fa/fa) rats in response to contraction, Diabetes, 51, 2703, 10.2337/diabetes.51.9.2703 · DOI · Paper page
  9. Rutter, 2003, Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis, Biochem J, 375, 1, 10.1042/bj20030048 · DOI · Paper page
  10. Thomson, 2008, AMP-activated protein kinase phosphory-lates transcription factors of the CREB family, J Appl Physiol, 104, 429, 10.1152/japplphysiol.00900.2007 · DOI · Paper page
  11. Saha, 2003, Malonyl-CoA and AMP-activated protein kinase: an expanding partnership, Mol Cell Biochem, 253, 65, 10.1023/A:1026053302036 · DOI · Paper page
  12. Cignarella, 2006, Hypolipidemic therapy for the metabolic syndrome, Pharmacol Res, 53, 492, 10.1016/j.phrs.2006.03.012 · DOI
  13. Desvergne, 1999, Peroxisome proliferator-activated receptors: nuclear control of metabolism, Endocr Rev, 20, 649
  14. Misra, 2008, AMP activated protein kinase: a next generation target for total metabolic control, Expert Opin Ther Targets, 12, 91, 10.1517/14728222.12.1.91 · DOI · Paper page
  15. Dobrzyn, 2005, Polyunsaturated fatty acids do not activate AMP-activated protein kinase in mouse tissues, Biochem Biophys Res Commun, 332, 892, 10.1016/j.bbrc.2005.05.026 · DOI
  16. Suchankova, 2005, Dietary polyunsaturated fatty acids enhance hepatic AMP-activated protein kinase activity in rats, Biochem Biophys Res Commun, 326, 851, 10.1016/j.bbrc.2004.11.114 · DOI
  17. Mancini, 2001, Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats, FEBS Lett, 491, 154, 10.1016/S0014-5793(01)02146-9 · DOI · Paper page
  18. Naderali, 2004, Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats, Atherosclerosis, 177, 307, 10.1016/j.atherosclerosis.2004.07.029 · DOI
  19. Duncombe, 1963, The colorimetric micro-determination of long-chain fatty acids, Biochem J, 88, 7, 10.1042/bj0880007 · DOI · Paper page
  20. Braissant, 1996, Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat, Endocrinology, 137, 354, 10.1210/endo.137.1.8536636 · DOI · Paper page
  21. Cho, 2008, Peroxisome proliferator-activated receptor (PPAR) modulators and metabolic disorders, PPAR Res, 2008, 679137, 10.1155/2008/679137 · DOI · Paper page
  22. Yu, 2003, Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis, Curr Mol Med, 3, 561, 10.2174/1566524033479537 · DOI · Paper page
  23. Morash, 2009, Effects of dietary fatty acid composition on the regulation of carnitine palmitoyltransferase (CPT) I in rainbow trout (Oncorhynchus mykiss), Comp Biochem Physiol B Biochem Mol Biol, 152, 85, 10.1016/j.cbpb.2008.10.005 · DOI
  24. Bai, 2008, Effects of fenofibrate on gene expression of carnitine palmitoyltransferase 1 in liver and skeletal muscle and its influence on insulin sensitivity, Zhonghua Yi Xue Za Zhi, 88, 268
  25. Yang, 2008, Chronic activation of AMP-activated protein kinase-alpha1 in liver leads to decreased adiposity in mice, Biochem Biophys Res Commun, 370, 248, 10.1016/j.bbrc.2008.03.094 · DOI
  26. Lawrence, 2004, Medical consequences of obesity, Clin Dermatol, 22, 296, 10.1016/j.clindermatol.2004.01.012 · DOI · Paper page
  27. Hashem, 2008, Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steato-hepatitis, Eur J Gastroenterol Hepatol, 10, 995, 10.1097/MEG.0b013e3282fdf65f · DOI
  28. Zhou, 1995, Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans, J Clin Endocrinol Metab, 80, 1584
  29. DeFronzo, 1992, Pathogenesis of NIDDM. A balanced overview, Diabetes Care, 15, 318, 10.2337/diacare.15.3.318 · DOI · Paper page
  30. Dohm, 1988, An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects, J Clin Invest, 82, 486, 10.1172/JCI113622 · DOI · Paper page
  31. Oatey, 1997, GLUT4 vesicle dynamics in living 3T3 L1 adipocytes visualized with green-fluorescent protein, Biochem J, 327, 637, 10.1042/bj3270637 · DOI · Paper page
  32. Ryder, 2001, Intracellular mechanisms underlying increases in glucose uptake in response to insulin or exercise in skeletal muscle, Acta Physiol Scand, 171, 249, 10.1046/j.1365-201x.2001.00827.x · DOI · Paper page
  33. Koistinen, 2003, 5-Amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes, Diabetes, 52, 1066, 10.2337/diabetes.52.5.1066 · DOI · Paper page
  34. Kurth-Kraczek, 1999, 5′ AMP-activated protein kinase activation causes GLUT4 translocation in skeletal muscle, Diabetes, 48, 1667, 10.2337/diabetes.48.8.1667 · DOI · Paper page
  35. Moore, 1996, The nerves, the liver, and the route of feeding: an integrated response to nutrient delivery, Nutrition, 12, 282, 10.1016/S0899-9007(97)85073-4 · doi:10.1016/s0899-9007(97)85073-4
  36. Burcelin, 2003, GLUT4, AMP kinase, but not the insulin receptor, are required for hepatoportal glucose sensor-stimulated muscle glucose utilization, J Clin Invest, 111, 1555, 10.1172/JCI200316888 · DOI

Cited by

Metadata

Authors
Motawi, T. M. K., Hashem, R. M., Rashed, L. A., & El-Razek, S. M. A.
Venue
Journal of Pharmacy and Pharmacology
Published
2009-10-01
Volume
61
Issue
10
Pages
1339-1346
ISSN
  • 0022-3573 (ISSN-L)
  • 2042-7158
OpenAlex
W2095463380
Cited by
30
References
8
FWCI
1.32
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.